Trends and Controversies in Global Gynecologic Oncology: Diagnosis and Management

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 6509

Special Issue Editors


E-Mail Website
Guest Editor
1. Doctoral School, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania
2. Institute of Global Health Equity Research, Kigali, Rwanda
Interests: global oncology; cervical cancer; cancer equity

E-Mail Website
Guest Editor
1. Department of Surgery, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2. The Institute of Oncology in Bucharest, Bucharest, Romania
Interests: general surgery, oncology surgery, laparoscopic surgery; palliative care; health services management; hospitals evaluation and accreditation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the trends and controversies in global gynecologic oncology (specifically the areas of diagnosis and management), addressing the current approaches in LMIC compared to HIC and innovative interventions.

Topics of interest for this Special Issue include (but are not limited to) the following:

  • Cervical cancer in Eastern Europe (diagnosis and management);
  • Gynaecological oncology: cancer resources in diagnosis and cost evaluation of main cancers in females in different settings;
  • Review of global gynaecologic oncology;
  • Technology and innovations in diagnosis in gynaecologic oncology in LMIC;
  • Trends in gynaecology oncology research;
  • Cervical cancer in Africa (diagnosis and management);
  • Cervical cancer in Asia (diagnosis and management).

Prof. Dr. Daniela-Cristina Stefan
Prof. Dr. Laurentiu Simion
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • global gynecology
  • oncology
  • diagnosis
  • management
  • low- and mid-income countries
  • health equity
  • innovation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 1793 KiB  
Article
Venous Thromboembolism Prophylaxis in Gynecologic Oncology: A MITO-MaNGO Survey
by Michele Mongelli, Domenica Lorusso, Vanna Zanagnolo, Sandro Pignata, Nicoletta Colombo and Gennaro Cormio
Diagnostics 2024, 14(11), 1159; https://doi.org/10.3390/diagnostics14111159 - 31 May 2024
Viewed by 574
Abstract
Cancer-associated thrombosis is the second leading cause of death in cancer patients, and its incidence has been increasing in recent years. This survey was aimed at gathering information regarding the management of thromboembolic prophylaxis within the MITO (Multicenter Italian Trials in Ovarian Cancer)-MaNGO [...] Read more.
Cancer-associated thrombosis is the second leading cause of death in cancer patients, and its incidence has been increasing in recent years. This survey was aimed at gathering information regarding the management of thromboembolic prophylaxis within the MITO (Multicenter Italian Trials in Ovarian Cancer)-MaNGO (Mario Negri Gynecologic Oncology) groups. We designed a self-administered, multiple-choice online questionnaire available only for MITO-MaNGO members for one month, starting in May 2022 and ending in June 2022. We processed one response form per center, and 50 responses were analyzed, with most of the respondents (78%) over 40 years old. We found that 82% of them consider thromboembolic prophylaxis in gynecologic oncology to be relevant. In 82% of the centers, a standardized protocol on venous thromboembolism (VTE) prophylaxis is used, which is applied to both patients undergoing surgery and those undergoing chemotherapy. In the remaining 18% of centers, prophylaxis is used exclusively for patients undergoing chemotherapy treatment. Prophylaxis of patients undergoing surgery and chemotherapy treatment is managed in most cases by the surgeon (72%) and oncologist (76%), respectively. Only 26% of respondents use a thromboembolic risk assessment scale, and of these, those used are the Caprini Score (6%), Khorana Score (6%), and Wells Score (2%). The respondents have good knowledge of low-molecular-weight heparin (90%) and average knowledge of dicumarolics (40%), direct oral anticoagulants (DOACs) (68%), and antiplatelet agents (40%). The results of our survey indicate that there is a good awareness of thromboembolic prophylaxis in gynecologic oncology. Nevertheless, it is used less in outpatients than in patients undergoing surgery. Moreover, the thromboembolic risk assessment scores are barely used. Full article
Show Figures

Figure 1

19 pages, 8136 KiB  
Article
Myxoid Endometriosis: An Entity That Can Cause Confusion with Malignant Entities
by Saulo Mendoza-Ramirez, Claudia Mariana Hernández-Robles, Italú Velasco-Rueda, Alejandra Romero-Utrilla, Myrna Doris Arrecillas-Zamora, Eduardo Agustín-Godínez, Lourdes Lucía Morales-Jáuregui, Lázaro Ariel Ramírez-Balderrama, Marco Antonio Olvera-Olvera and Mario Murguia-Perez
Diagnostics 2023, 13(20), 3176; https://doi.org/10.3390/diagnostics13203176 - 11 Oct 2023
Viewed by 1197
Abstract
Myxoid endometriosis, a rare entity, is part of the histological changes that can occur in endometriosis. Pathologists must know the histological guidelines for the morphological recognition of this entity, as well as the histochemical and immunohistochemical techniques that support diagnosis, and define the [...] Read more.
Myxoid endometriosis, a rare entity, is part of the histological changes that can occur in endometriosis. Pathologists must know the histological guidelines for the morphological recognition of this entity, as well as the histochemical and immunohistochemical techniques that support diagnosis, and define the morphological characteristics of myxoid endometriosis. In the present work, we propose diagnostic guidelines and primary differential diagnoses using special histochemical techniques and immunohistochemical reactions to recognize this entity. Full article
Show Figures

Figure 1

19 pages, 4263 KiB  
Article
Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Axillary Conversion after Neoadjuvant Chemotherapy—A Single-Tertiary Centre Experience and Review of the Literature
by Alexandra Maria Lazar, Mario-Demian Mutuleanu, Paula Monica Spiridon, Cristian Ioan Bordea, Tatiana Lucia Suta, Alexandru Blidaru and Mirela Gherghe
Diagnostics 2023, 13(18), 3000; https://doi.org/10.3390/diagnostics13183000 - 20 Sep 2023
Viewed by 1724
Abstract
(1) Introduction: Sentinel lymph node biopsy (SLNB) is widely used in breast cancer patients who undergo neoadjuvant chemotherapy (NAC), replacing axillary lymph node dissection. While commonly accepted for cN0 patients, its role in cN1/2 patients remains controversial. Our study aims to investigate the [...] Read more.
(1) Introduction: Sentinel lymph node biopsy (SLNB) is widely used in breast cancer patients who undergo neoadjuvant chemotherapy (NAC), replacing axillary lymph node dissection. While commonly accepted for cN0 patients, its role in cN1/2 patients remains controversial. Our study aims to investigate the role of SLNB in BC patients who underwent prior NAC and compare our results to those of other studies presented in the literature. (2) Materials and methods: Our retrospective study included 102 breast cancer patients who received NAC before 99mTc-albumin Nanocolloid SLN mapping and SLNB was performed, completed or not with axillary dissection. A review based on the PRISMA statement was also carried out, encompassing 20 studies. (3) Results: The lymphoscintigraphy performed after the administration of NAC presented an identification rate (IR) of 93.13%. IR for SLNB was 94.11%, with a false-negative rate (FNR) of 7.4%. After a median follow-up of 31.3 months, we obtained a distant disease-free survival rate of 98%. The results obtained by other groups were similar to those of our study, presenting IR in the range 80.8–96.8%, with FNR varying from 0 to 22%. (4) Conclusions: on conclusion, SLNB can accurately determine the lymph node status, with an acceptable FNR and maintain its expected prognostic role with low recurrence rates, and our results are comparable to those obtained by other studies. Full article
Show Figures

Figure 1

22 pages, 2209 KiB  
Article
Inequities in Screening and HPV Vaccination Programs and Their Impact on Cervical Cancer Statistics in Romania
by Laurentiu Simion, Vlad Rotaru, Ciprian Cirimbei, Laurentia Gales, Daniela-Cristina Stefan, Sinziana-Octavia Ionescu, Dan Luca, Horia Doran and Elena Chitoran
Diagnostics 2023, 13(17), 2776; https://doi.org/10.3390/diagnostics13172776 - 28 Aug 2023
Cited by 11 | Viewed by 2413
Abstract
(1) Introduction: A Romanian woman is diagnosed with cervical cancer every two hours; the country ranks second in Europe in terms of the mortality and incidence rate of this disease. This paper aims to identify the main reasons that have led to this [...] Read more.
(1) Introduction: A Romanian woman is diagnosed with cervical cancer every two hours; the country ranks second in Europe in terms of the mortality and incidence rate of this disease. This paper aims to identify the main reasons that have led to this situation, focusing on the measures taken by the Romanian Ministry of Health for the prevention of this type of cancer—national programs for cervical cancer screening and HPV vaccination. (2) Materials and methods: We performed a study based on the available secondary data from the National Statistics Institute, World Health Organization and Bucharest Institute of Oncology in order to assess the burden associated with cervical cancer and place it in the context of known global and European incidence and mortality rates, thus evaluating the importance of this health issue in Romania. The second component of our study was a cross-sectional study. Here, we used a 14-question questionnaire applied to the women participating in the National Screening Program for Cervical Cancer and aimed to evaluate the women’s level of knowledge about screening and HPV vaccination and their access cervical-cancer-specific healthcare services. (3) Results: The results of this research show that a high percentage of women postpone routine checks due to a lack of time and financial resources and indicate that a low level of knowledge about the disease and the specific preventive methods determines the low participation in screening and HPV vaccination programs implemented in Romania, contributing to the country’s cervical cancer situation. (4) Conclusions: The national programs have complicated procedures, are underfunded and do not motivate healthcare workers enough. This, combined with the lack of information for the eligible population, adds up to an extremely low number of women screened and vaccinated. Our conclusion is that the Romanian Ministry of Health must take immediate action by conducting major awareness campaigns, implementing measures to make the programs functional and ensuring coherent funding. Full article
Show Figures

Figure 1

Back to TopTop